Low ‐dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti‐thymocyte globulin
Transplant Infectious Disease, EarlyView.
Source: Transplant Infectious Disease - Category: Transplant Surgery Source Type: research
More News: Cardiology | Cytomegalovirus | Heart | Heart Transplant | Infectious Diseases | Transplant Surgery | Transplants